Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience

Lung India

Volumn 31, Issue 4, 2014, Pages 354-360

  Kundu, Somenath ^a   Mitra, Subhra ^b   Ganguly, Joydeep ^c   Mukherjee, Subhasis ^d   Ray, Souvik ^e   Mitra, Ritabrata ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b CALCUTTA NATIONAL MEDICAL COLLEGE   (India)

^c Murshidabad Medical College and Hospital   (India)

^d Department of Obstetrics and Gynaecology   (India)

^e BANKURA SAMMILANI MEDICAL COLLEGE   (India)

Author keywords

Connective tissue disease associated diffuse parenchymal lung diseases; diffuse parenchymal lung diseases; idiopathic pulmonary fibrosis

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; CALCIUM; CENTROMERE ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; SCL 70 ANTIBODY;

ADULT; ALLERGIC PNEUMONITIS; ANCA ASSOCIATED VASCULITIS; ANKYLOSING SPONDYLITIS; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CHURG STRAUSS SYNDROME; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIFFUSE PARENCHYMAL LUNG DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; ENVIRONMENTAL MANAGEMENT; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; HYPERTENSION; INTERSTITIAL PNEUMONIA; LANGERHANS CELL HISTIOCYTOSIS; LOW DRUG DOSE; LUNG BIOPSY; LUNG CARCINOMA; LUNG DISEASE; LUNG SARCOIDOSIS; LUNG TUBERCULOSIS; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; OBSERVATIONAL STUDY; OXYGEN DESATURATION; OXYGEN SATURATION; POLYMYOSITIS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SILICOSIS; SMALL VESSEL VASCULITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS;

EID: 84908472879     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.142115     Document Type: Article

References (37)

1. American Thoracic Society; European Respiratory Society.American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.Am J Respir Crit Care Med 2002;165:277-304.
2. Thiruvengadam KV, Chandrasekaran AN, Kulandaivelu V, Inbavazhvu MN, Venkatramani K. Pleuro pulmonary manifestations of rheumatoid arthritis. Indian J Chest Dis Allied Sci 1979;21:35-43.
3. Guleria JS, Pande JN, Malik SK, Bhutani LK. Lungs in progressive systemic sclerosis. Br J Dis Chest 1970;64:150-60.
4. Sharma SK, Pande JN, Guleria JS. Diffuse interstitial pulmonary fibrosis. Indian J Chest Dis Allied Sci 1984;26:214-9.
5. Jindal SK, Malik SK, Deodhar SD, Sharma BK. Fibrosingalveolitis: A report of 61 cases seen over thepast five years. Indian J Chest Dis Allied Sci 1979;21:174-9.
6. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment.International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).Am J Respir Crit Care Med 2000;161:646-64.
7. Sen T, Udwadia ZF.Retrospective study of interstitial lung disease in a tertiary care centre in India. Indian J Chest Dis Allied Sci 2010;52:207-11.
8. Maheshwai U, Gupta D, Aggarwal AN, Jindal SK. Spectrum and diagnosis of idiopathic pulmonary fibrosis.Indian J Chest Dis Allied Sci 2004;46:23-6.
9. Subhash HS, Ashwin I, Solomon SK, David T, Cherian AM, Thomas K. A comparative study on idiopathic pulmonary fibrosisand secondary diffuse parenchymal lung disease. Indian J Med Sci 2004;58:185-90.
10. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013;143:814-24.
11. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
12. Gali; N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. ESCCommittee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
13. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: Idiopathic Pulmonary Fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
14. Costable U, Bonella F, Guzman J. Chronic hypersensitivity pneumonitis. Clin Chest Med 2012;33:151-63.
15. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42.
16. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
17. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009;33:882-96.
18. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee February 1999. Am J Respir Crit Care Med 1999 160 736-55.
19. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegeners granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years.Ann Intern Med 1983;98:76-85.
20. Udwadia ZF, Sen T, Jindal SK. Interstitial lung diseases in a resource-limited setting: The case of India. Eur Respir Mon 2009;46:357-74.
21. Sen T, Udwadia ZF. Cryptogenic organizing pneumonia: Clinical profile in a series of 34 admitted patients in a hospital in India. J Assoc Physicians India 2008;56:229-32.
22. Doshi AV, Udwadia ZF. A profile of sarcoidosis from a private hospital in Bombay. Chest 2002;122:146S-7S.
23. Johnston ID, Prescott RJ, Chalmers JC, Rudd RM. British Thoracic Society study of cryptogenic fibrosingalveolitis: Current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997;52:38-44.
24. Rajasekaran BA, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis: A comparison with cryptogenic fibrosingalveolitis. Rheumatology (Oxford) 2001;40:1022-5.
25. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-52.
26. Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev 2013;22:6-19.
27. Kim EA, Lee KS, Johkoh T, Kim TS, Suh GY, Kwon OJ, et al. Interstitial lung diseases associated with collagen vascular diseases: Radiologic and histopathologic findings. Radiographics 2002;22:S151-65.
28. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2011 184 1382-89.
29. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al Six-minute-walk test in idiopathic pulmonary fibrosis: Test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011 183 1231-7.
30. Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S, et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 2009;103:117-23.
31. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42.
32. Wells AU, Behr J, Costabel U, Cottin V, Poletti V. Triple therapy in idiopathic pulmonary fibrosis: An alarming press release. Eur Respir J 2012;39:805-6.
33. Kocheril SV, Appleton BE, Somers EC, Kazerooni EA, Flaherty KR, Martinez FJ, et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 2005;53:549-57.
34. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosingalveolitis. Rheumatology (Oxford) 2002;41:676-9.
35. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: Idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007;175:705-11.
36. Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008;10:R124.
37. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosingalveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-6.